AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01915537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic DMARDs treatment group
Description: Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.~Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time.
Study NCT02782351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T
Description: Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
Study NCT02339844 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: 6 weeks of individual doses of aripiprazole
Study NCT02748499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Beat Accupunch (HBA) exercise program
Description: HBA has three phases and takes 40 minutes to complete.
Study NCT02748499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants maintain their daily acitvities.
Study NCT01530503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine and mitomycin
Description: oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
Study NCT01530503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.~Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months
Study NCT04285554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iRF System Hepatic Denervation
Description: The iRF System is a percutaneous, catheter-based device which uses RF energy to circumferentially denervate the sympathetic nerves surrounding the common hepatic artery (CHA).
Study NCT01113840 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Exercise classes three times per week in a controlled, supervised environment.
Study NCT01113840 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control group continues daily life as prior to randomization.
Study NCT03265145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stiolto Respimat
Description: Duration - 12 months
Study NCT03265145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICS (Inhaled Corticosteroid) (Triple therapy)
Description: Duration - 12 months
Study NCT03265145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LABA (Long-Acting Beta Agonist) (Triple therapy)
Description: Duration - 12 months
Study NCT03265145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Description: Duration - 12 months
Study NCT01941654 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: preemptive local ablative therapy
Study NCT01941654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral TKI
Study NCT01872975 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: regional nodal XRT
Study NCT01872975 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chestwall XRT
Study NCT01872975 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: WBI
Study NCT01872975 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: WBI
Study NCT02544867 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary behavior
Description: Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
Study NCT02855879 — intervention group
Intervention type: OTHER
Intervention: Collection of biological data
Study NCT02855879 — intervention group
Intervention type: OTHER
Intervention: Collection of clinical data
Study NCT04781790 — intervention group
Intervention type: OTHER
Intervention: Bone Marrow Failure
Description: without interventional intervention . biological collection in the routine care Standard of care of patients with bone marrow failure.
Study NCT02765100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline 100 mg twice a day
Study NCT00706875 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: A patient questionnaire, which includes validated instruments. Data collection methods are as follows:~* In person at the medical appointment~* Over the telephone~* Mailed with self-addressed return envelope and prepaid postage~* E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage
Study NCT01349985 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AGATE
Description: AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
Study NCT01349985 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SASED
Description: Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
Study NCT03291158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
Study NCT04605159 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT
Description: One dose of RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm at Day 1.
Study NCT04605159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (lyophilized sucrose reconstituted with NaCl solution) administered intramuscularly in the non-dominant arm at Day 1.
Study NCT05851794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endomanometric guided LNF
Description: use of endomanometry during LNF
Study NCT05851794 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic Nissen fundoplication alone
Description: laparoscopic Nissen fundoplication alone
Study NCT01494415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel for Injection（Albumin Bound）
Description: concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
Study NCT01494415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
Study NCT01494415 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiation therapy
Description: 66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
Study NCT01181440 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermagraft(R)
Description: Weekly application of Dermagraft(R) with conventional care
Study NCT01181440 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional care
Description: Weekly application of conventional care
Study NCT01101243 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1 SED every week
Study NCT03047798 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mouthrinse
Description: A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.
Study NCT03047798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthrinse
Description: A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.~Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen.
Study NCT04114071 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women
Description: See arm description
Study NCT01101243 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 4 SED every second week
Study NCT01101243 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1 SED every second week
Study NCT01101243 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Broadband UVB
Description: UVB dose: 1 SED every month
Study NCT01101243 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control group
Description: No intervention
Study NCT01236794 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Education Sessions and Youth Exercise Sessions
Description: The intervention will include a \~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (\~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
Study NCT04114071 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOSS Feasibility + Fitbit Community = Reduced Obesity in Older Black Women
Description: See arm description
Study NCT03267784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allo-APZ2-DFU
Description: Suspension of ABCB5-positive mesenchymal stem cells
Study NCT00752921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoricoxib
Description: 120 mg
Study NCT00752921 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT04503863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of middle dose NPC-22
Study NCT04503863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-22
Description: Single administration of high dose NPC-22
Study NCT04503863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-22 Placebo
Description: Single administration of NPC-22 Placebo
Study NCT04005807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN-14967
Description: BPN-14967 oral capsules
Study NCT04005807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral capsules
Study NCT03819270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3372689
Description: Administered orally
Study NCT03819270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT04173039 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serum anti-CarP antibodies detection
Description: Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.
Study NCT02924727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan)
Description: LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
Study NCT02924727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
Study NCT01084343 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MYM-V101
Description: * Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.~* Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks.
Study NCT02453750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypersaline
Description: Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls \<10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls >10%, the previous step will be repeated.
Study NCT02453750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bronchodilator Response
Description: A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
Study NCT02924727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696
Description: Matching placebo of LCZ696 tablets
Study NCT02924727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of ramipril
Description: Matching placebo of ramipril capsule
Study NCT00961831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 (BAY85-8050)
Description: Cancer patients, injection of BAY 85-8050, PET/CT
Study NCT00961831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 (BAY85-8050)
Description: Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
Study NCT02924727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
Study NCT02924727 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of valsartan
Description: matching placebo of valsartan for one day to patients who will be randomized to received ramipril
Study NCT00863395 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: Lidocaine 1% c Epinephrine for local anesthesia
Study NCT02860221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: IV and topical administration
Study NCT02860221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: IV and topical administration
Study NCT02860221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epinephrine
Study NCT03163524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-Coupon Text Modification and Reminders
Description: The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
Study NCT03163524 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: e-Coupon standard text
Description: Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
Study NCT01910974 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic sub-mucosal dissection
Description: endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
Study NCT02433262 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WHO (World Health Organisation)
Description: Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
Study NCT02433262 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IADPSG
Description: Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
Study NCT02143635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDM201
Study NCT02143635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ancillary treatment
Study NCT02623348 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pedometer
Description: pedometer-based physical activity recommendations
Study NCT04809935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 98% dehydrated alcohol
Description: * coeliac plexus is identified and punctured~* Injection of 10 mL of .25% bupivacaine, followed by 10 mL of 98% dehydrated alcohol.
Study NCT04809935 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 19G EUSRA needle, Taewoong Medical, Korea
Description: * 10W-30W RFA will be applied unilaterally or bilaterally depends on individual anatomical characteristics for 10-50s~* Complete ablation of coeliac plexus nervous tissue is confirmed by appearance of air-bubble ultrasound scan
Study NCT03659097 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: periodontally accelerated osteogenic orthodontics
Description: Surgery will be performed to the lower anterior bony segment of the lower jaw in order to accelerate tooth movement
Study NCT06367491 — intervention group
Intervention type: OTHER
Intervention: Registration in a database
Description: All patients with bone metastasis enrolled at the centre will be entered into the database and followed until death or interruption of follow-up for any another cause
Study NCT01662349 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MOE Antimicrobial Plasma Treatment System
Description: Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
Study NCT01527084 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: surgical intervention after percutaneous catheter drainage
Description: Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
Study NCT01406392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 25mcg
Description: Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
Study NCT01406392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual Misoprostol
Description: Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
Study NCT03974932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTX-011
Description: Dual-acting local anesthetic. Dose 1.
Study NCT03974932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: NSAID.
Study NCT00604955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paromomycin sulfate
Description: Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days